Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Phillip Levy

Emergency Medicine Detroit, MI Medical Doctor

NPI 1063473478 CMS profile 3180

4201 Saint Antoine St, Detroit, MI 48201

Open in the dashboard

General payments

$177,268

112 records reported · program years 2019–2024

Research payments

$101,200

Paid to them · 9 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$535,158 paid to institutions, not to them · program years 2019–2020

Through program year 2024, Phillip Levy of Detroit, MI is reported in the CMS Open Payments database as having received $177,268 across 112 general payments and $101,200 in research payments paid to them. Separately, studies naming them as principal investigator received $535,158 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $61,670 5
2023 General $38,871 30
2022 General $26,951 24
2021 General $18,704 11
2020 General $22,185 21
2020 Research $26,200 7
2019 General $8,888 21
2019 Research $75,000 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Phillip Levy
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Phillip Levy were reported at $0. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Phillip Levy Emergency Medicine median Middle half National median
2019 $8,888 $51 $18–$128 $163
2020 $22,185 $29 $16–$99 $114
2021 $18,704 $40 $18–$124 $132
2022 $26,951 $49 $20–$134 $149
2023 $38,871 $51 $22–$142 $160
2024 $61,670 $52 $22–$150 $164
2025 $0 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Beckman Coulter, Inc. $86,570 39 payments
  2. Siemens Medical Solutions USA, Inc. $21,975 19 payments
  3. Pfizer Inc. $17,651 4 payments
  4. Roche Diagnostics Corporation $13,162 14 payments
  5. Ultrasight Inc $9,415 1 payment
  6. Novartis Pharmaceuticals Corporation $6,778 4 payments
  7. AstraZeneca Pharmaceuticals LP $3,741 5 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $3,143 1 payment
  9. Quidel Corporation $3,069 3 payments
  10. Polymedco, LLC $3,000 2 payments
  11. Other $8,764 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $153,967 73 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $9,600 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,400 2 payments
  4. Travel and Lodging $2,984 8 payments
  5. Food and Beverage $1,816 26 payments
  6. Honoraria $1,500 1 payment
Products named General payments · program years 2019–2024
  1. CHANTIX $17,141 3 payments
  2. UltraSight AI Guidance $9,415 1 payment
  3. CD cobas Reagents $7,262 13 payments
  4. ENTRESTO $5,928 3 payments
  5. DXI 800 $4,300 4 payments
  6. ACCESS 2 $4,300 4 payments
  7. DXI 600 $4,300 4 payments
  8. LOKELMA $3,609 4 payments
  9. DXH 900 Hematology $1,600 3 payments
  10. DXH 900 Devices $1,400 3 payments
  11. Other $3,783 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Ortho-Clinical Diagnostics, Inc. $101,200 9 payments

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$8,797

Of which drugs: $6,304

Medicare patients

48

Average age 80

Services billed

119

36 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 40%
Heart failure 31%
Ischemic heart disease 31%
Chronic kidney disease 29%
Atrial fibrillation 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 40 40 $5,789

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

121 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record